The 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)
ASCO GU 2025 Prostate Cancer
- ASCO GU 2025: A Prospective Trial of a Structured Exercise Program to Lessen Fatigue in Patients with Advanced Prostate Cancer Undergoing ADT
- ASCO GU 2025: Radium-223 Without ADT in Patients with Biochemically Recurrent Prostate Cancer and PET Findings in the Bones
- ASCO GU 2025: PREP - A Prospective Provincial Registry of PSMA PET CT for Recurrent Prostate Cancer: Results for 4,135 Men
- ASCO GU 2025: Beyond PSMA-Targeted Agents for Advanced Disease
- ASCO GU 2025: Comparing Progression Following Systemic and Tumor-Directed Therapy for De Novo Versus Recurrent PSMA PET–defined Oligo-M1 Prostate Cancer: A Pooled Analysis of SOLAR and SATURN Clinical Trials
ASCO GU 2025 Bladder Cancer
- ASCO GU 2025: Targeting Bladder Cancer with Antibody Drug Conjugates
- ASCO GU 2025: Overcoming Challenges of Antibody Drug Conjugate Toxicity in Bladder Cancer
- ASCO GU 2025: Better Together? Exploring Novel Drug Combinations with Antibody Drug Conjugates
- ASCO GU 2025: HER2 Antibody Drug Conjugate Therapy: A New Frontier in Bladder Cancer
- ASCO GU 2025: Nectin-4 Targeted ADC, SHR-A2102, in Patients With Advanced or Metastatic Urothelial Carcinoma: A Phase 1 Study
ASCO GU 2025 Kidney Cancer
- ASCO GU 2025: Case-Based Session: Failure of Immunotherapy in Renal Cell Cancer – What’s Next
- ASCO GU 2025: Adjuvant Therapy in Renal Cell Cancer: A Practical Guide
- ASCO GU 2025: Biomarkers in Renal Cell Carcinoma: Dead End or Turning Point?
- ASCO GU 2025: The Future of Biomarkers in Renal Cell Carcinoma
- ASCO GU 2025: Final Overall Survival and New ctDNA Analysis in MET-Driven Advanced Papillary Renal Cancer (CALYPSO)
ASCO GU 2025 Upper Tract Urothelial Carcinoma
- ASCO GU 2025: Capturing What You Cannot See: How Can ctDNA Be Used to Improve Clinical Staging for Upper Tract Disease?
- ASCO GU 2025: Updated Long-Term Follow-up from a Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients with High-Grade Upper Tract Urothelial Carcinoma.
- ASCO GU 2025: Discussant: Advancements in Urothelial Cancer Perioperative Therapy
- ASCO GU 2025: Kidney-Sparing Approach for Selected Localized High-Risk Upper Tract Urothelial Carcinoma: A Pilot Study Combining Endoscopic Thulium Laser Ablation With Perioperative Disitamab Vedotin and Immune Checkpoint Inhibitors
- ASCO GU 2025: iNDUCT: Safety and Efficacy of Neoadjuvant Immunotherapy with Durvalumab in Combination with Neoadjuvant Chemotherapy (Gemcitabine/cisplatin or Carboplatin) in Patients with Operable High-Risk Upper Tract Urothelial Carcinoma
ASCO GU 2025 Penile, Urethral, Testicular, and Adrenal Cancers
- ASCO GU 2025: Landscape of New Trials and Targets in Refractory Germ Cell Tumors
- ASCO GU 2025: Primary Retroperitoneal Lymph Node Dissection in Stage II Seminoma: Management Strategies and Current Controversies
- ASCO GU 2025: High-Dose Chemotherapy in Testicular Cancer: Current Evidence and Clinical Indications
- ASCO GU 2025: EPIC-A: Phase II Trial of Cemiplimab plus Standard of Care Chemotherapy Followed by Maintenance Cemiplimab in Locally Advanced or Metastatic Penile Carcinoma
- ASCO GU 2025: EPIC-B: Phase II Trial of Cemiplimab as First-Line Treatment in Advanced Penile Carcinoma
ASCO GU 2025 Press Releases
- Bladder Cancer: Upstaging and Risk Mitigation with Blue Light Cystoscopy in NMIBC Featured at ASCO GU 2025
- Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium
- Bayer Unveils Latest Data from Prostate Cancer Portfolio at 2025 ASCO GU Cancers Symposium
- Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
- Mobile Prostate Cancer Screening Clinic Can Help Address Barriers to Serving High-Risk Communities